The future of radiotherapy is molecular
- PDF / 886,628 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 99 Downloads / 197 Views
TOPICAL DEBATE
The future of radiotherapy is molecular Dale L. Bailey1,2 · Wendy Philips3 · Clive Baldock4 Published online: 17 August 2020 © Australasian College of Physical Scientists and Engineers in Medicine 2020
Introduction and overview: Clive Baldock, moderator Very soon after the discovery of X-rays by Wilhelm Röntgen in 1895, radiation was beginning to be used to treat cancer. The field of radiotherapy, or radiation therapy, has continued to grow and evolve for over 125 years as a treatment for cancer with the translation of fundamental research through to clinical practice. In recent decades there has been significant changes in radiotherapy enabled by technological and biological advances. Clinical outcomes have improved through the introduction of innovations such as IMRT and IGRT, the use of novel therapeutic radionuclides, particle beams and the availability of advanced imaging techniques such as CT, PET, MRI. In this Topical Debate, the proposition to be debated is that the future of radiotherapy is molecular.1 Arguing for the Proposition is Professor Dale Bailey PhD. Prof Bailey was born and raised in Sydney and received his undergraduate and Master’s degrees in Physics from University of Technology Sydney (UTS). He undertook postgraduate training at Harvard Medical School working at Beth Israel Hospital, Boston after which he returned to Sydney in 1984 to a position in the Department of Nuclear
* Clive Baldock [email protected]
Medicine at Royal Prince Alfred Hospital, Sydney. While in this position Prof Bailey was awarded the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) Boyce Worthley Young Achiever Award for his work on simultaneous transmission/emission imaging in SPECT. Prof Bailey moved to London to work at the Medical Research Council Cyclotron Unit at Hammersmith Hospital in 1990. At the same time he commenced his doctoral studies at the University of Surrey. Prof Bailey was in the UK for nearly 10 years, finishing his time as the head of Nuclear Medicine Physics at Guy’s and St Thomas’s Hospital. He returned to Sydney in 2002 to be appointed Principal Physicist in Nuclear Medicine at Royal North Shore Hospital, Sydney where he remains to this day. He also has an appointment as Professor in the School of Health Sciences at the University of Sydney and in 2019 was appointed the Director of the Sydney Vital Translational Cancer Research Centre. He served as the President of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) from 2016 to 2018. Prof Bailey’s interests are primarily in quantitative imaging in nuclear medicine where he has made significant contributions in both SPECT and PET. More recently, prompted by the rapid expansion of radionuclide therapies for cancer treatment, he has established a radiobiology laboratory geared towards studying the effects of particle-emitting radionuclides on cancer cells to better understand how to optimise therapy.
Dale L. Bailey [email protected] Wendy Philips [email protected]
Data Loading...
